肌钙蛋白筛查与免疫检查点抑制剂治疗期间主要心血管不良事件
该回顾性多中心队列研究纳入2017—2022年两家三级肿瘤中心859例接受ICI治疗的成人(平均70.1岁,68.1%肺癌),比较系统性肌钙蛋白筛查(治疗首3个月≥2次非症状驱动检测)与常规临床评估。中位随访3.3个月,40例(4.7%)发生MACE,6例(0.7%)为ICI相关心肌炎;484例(56.3%)死亡,其中90.1%死于癌症。
要点
- ICI相关心肌炎发生率仅0.7%(6/859),全部MACE发生率4.7%(40/859)。
- 中位随访3.3个月,56.3%患者死亡,其中90.1%死于癌症,竞争风险显著影响MACE分析。
适用人群与场景
- 平均年龄70.1岁(SD 10.8),60.2%男性,68.1%为肺癌。
- 系统性筛查组定义为ICI治疗首3个月内≥2次非症状驱动的肌钙蛋白检测。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:回顾性、多中心队列研究,2家三级肿瘤中心,859例接受ICI治疗的成人。
- 主要终点:裁定MACE(ICI相关心肌炎、急性冠脉综合征、需住院的心衰、心源性猝死、心血管死亡),共40例(4.7%),其中ICI相关心肌炎6例(0.7%)。
- 中位随访3.3个月(IQR 1.3-7.2),484例(56.3%)死亡,其中436例(90.1%)死于癌症。
证据类型、等级与局限
- 证据类型:回顾性多中心队列研究。
- 局限:回顾性设计、仅2家中心、样本量有限、筛查组定义依赖非症状驱动检测、竞争风险显著(多数死亡源于癌症)、随访时间短。
对床旁实践的改变
- 该研究提示在未选择的晚期实体瘤老年患者中,普遍肌钙蛋白筛查的获益存疑,不应仅凭多变量合并终点结果推广普遍筛查。
- 竞争风险分析和倾向评分匹配后筛查与MACE无显著关联,临床决策时应考虑癌症死亡竞争风险对MACE评估的影响。
- 原文建议需进一步研究风险适配的筛查策略是否能在避免不必要中断治疗的同时改善结局。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Troponin monitoring is recommended for the early detection of immune checkpoint inhibitor (ICI)-associated myocarditis, but its utility as a universal screening tool for all cardiovascular (CV) toxic effects in patients with cancer treated with ICIs remains uncertain.
OBJECTIVE: To evaluate whether systematic troponin screening is associated with reduced major adverse CV events (MACEs) and mortality in patients receiving ICI therapy for cancer.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective, multicenter cohort study assessed adults treated with ICIs between January 1, 2017, and December 31, 2022, at 2 tertiary oncology centers. Patients undergoing systematic troponin screening (≥2 measurements during the first trimester of ICI therapy not prompted by symptoms) were compared with those undergoing clinical assessment without screening. Cross-sectional follow-up was undertaken between June 1, 2023, and June 30, 2024.
EXPOSURE: ICI therapy for solid cancer.
MAIN OUTCOMES AND MEASURES: The primary outcomes included adjudicated MACEs (ICI-associated myocarditis, acute coronary syndrome, heart failure requiring hospitalization, sudden cardiac death, and CV death). Multivariate Cox proportional hazards regression, Fine-Gray competing risk models, and propensity score matching were applied, with death from cancer considered a competing risk.
RESULTS: Of 859 patients (mean [SD] age, 70.1 [10.8] years; 517 [60.2%] male; 585 [68.1%] with lung cancer), 40 (4.7%) developed MACEs, including 6 (0.7%) with ICI-associated myocarditis; 484 (56.3%) died at a median follow-up of 3.3 (IQR, 1.3-7.2) months, mainly from cancer (436 [90.1%]). Routine troponin screening was associated with lower mortality combined with MACEs in multivariable models (hazard ratio, 0.56 [95% CI, 0.45-0.70]) (P < .001) but was not associated with MACEs after competitive risk analysis (hazard ratio, 0.56 [95% CI, 0.20-1.55]) (P = .27) or in a propensity score-matched cohort of 354 patients (hazard ratio, 0.49 [95% CI, 0.20-1.24]) (P = .13).
CONCLUSIONS AND RELEVANCE: In this cohort study, systematic troponin screening was not associated with MACEs in an older population with metastatic solid cancer after competitive risk analysis or propensity score matching. These findings suggest that the benefits of universal troponin monitoring are questionable among unselected patients with cancer who are receiving ICIs; further investigation is needed to determine whether risk-adapted screening improves outcomes while avoiding unnecessary interruptions of treatment.
参考来源
- Hamdi I, El Bèze N, Henriquez S, et al. Troponin Screening and Major Cardiovascular Adverse Events During Immune Checkpoint Inhibitor Therapy. JAMA Netw Open. 2026. PMID: 42479432. doi:10.1001/jamanetworkopen.2026.24168
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。